These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 32301057)

  • 1. Population pharmacokinetics of standard-dose meropenem in critically ill patients on continuous renal replacement therapy: a prospective observational trial.
    Onichimowski D; Będźkowska A; Ziółkowski H; Jaroszewski J; Borys M; Czuczwar M; Wiczling P
    Pharmacol Rep; 2020 Jun; 72(3):719-729. PubMed ID: 32301057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane.
    Padullés Zamora A; Juvany Roig R; Leiva Badosa E; Sabater Riera J; Pérez Fernández XL; Cárdenas Campos P; Rigo Bonin R; Alía Ramos P; Tubau Quintano F; Sospedra Martinez E; Colom Codina H
    J Antimicrob Chemother; 2019 Oct; 74(10):2979-2983. PubMed ID: 31335959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.
    Peng Y; Cheng Z; Xie F
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0082222. PubMed ID: 36005753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy.
    Isla A; Rodríguez-Gascón A; Trocóniz IF; Bueno L; Solinís MA; Maynar J; Sánchez-Izquierdo JA; Pedraz JL
    Clin Pharmacokinet; 2008; 47(3):173-80. PubMed ID: 18307371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation.
    O'Jeanson A; Larcher R; Le Souder C; Djebli N; Khier S
    Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):695-705. PubMed ID: 34403127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meropenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy.
    Chaijamorn W; Rungkitwattanakul D; Pattharachayakul S; Singhan W; Charoensareerat T; Srisawat N
    J Crit Care; 2020 Dec; 60():285-289. PubMed ID: 32949895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal Dosing of Meropenem in a Small Cohort of Critically Ill Children Receiving Continuous Renal Replacement Therapy.
    Tan WW; Watt KM; Boakye-Agyeman F; Cohen-Wolkowiez M; Mok YH; Yung CF; Chan YH
    J Clin Pharmacol; 2021 Jun; 61(6):744-754. PubMed ID: 33314163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetics Analysis and Dosing Simulations Of Meropenem in Critically Ill Patients with Pulmonary Infection.
    Lan J; Wu Z; Wang X; Wang Y; Yao F; Zhao BX; Wang Y; Chen J; Chen C
    J Pharm Sci; 2022 Jun; 111(6):1833-1842. PubMed ID: 35090867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis.
    Ehmann L; Zoller M; Minichmayr IK; Scharf C; Huisinga W; Zander J; Kloft C
    Int J Antimicrob Agents; 2019 Sep; 54(3):309-317. PubMed ID: 31229669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
    Burger R; Guidi M; Calpini V; Lamoth F; Decosterd L; Robatel C; Buclin T; Csajka C; Marchetti O
    J Antimicrob Chemother; 2018 Dec; 73(12):3413-3422. PubMed ID: 30304491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of meropenem in critically ill children with different renal functions.
    Rapp M; Urien S; Foissac F; Béranger A; Bouazza N; Benaboud S; Bille E; Zheng Y; Gana I; Moulin F; Lesage F; Renolleau S; Tréluyer JM; Hirt D; Oualha M
    Eur J Clin Pharmacol; 2020 Jan; 76(1):61-71. PubMed ID: 31654149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements.
    Ulldemolins M; Soy D; Llaurado-Serra M; Vaquer S; Castro P; Rodríguez AH; Pontes C; Calvo G; Torres A; Martín-Loeches I
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5520-8. PubMed ID: 26124172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis.
    Pařízková RČ; Martínková J; Havel E; Šafránek P; Kaška M; Astapenko D; Bezouška J; Chládek J; Černý V
    Crit Care; 2021 Jul; 25(1):251. PubMed ID: 34274013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal Meropenem Dosing Regimens in Patients Undergoing Continuous Renal Replacement Therapy: Systematic Review and Monte Carlo Simulations.
    Charoensareerat T; Chaijamorn W; Kerdnimith P; Kosumwisaisakul N; Teeranaew P; Rungkitwattanakul D; Boonpeng A; Srisawat N; Pattharachayakul S
    Blood Purif; 2023; 52(6):503-515. PubMed ID: 37231811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of factors affecting meropenem pharmacokinetics in critically ill patients: Impact of inflammation on clearance.
    Niibe Y; Suzuki T; Yamazaki S; Uchida M; Suzuki T; Takahashi N; Hattori N; Nakada TA; Ishii I
    J Infect Chemother; 2022 Apr; 28(4):532-538. PubMed ID: 34973877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of meropenem in children with sepsis undergoing extracorporeal life support: A prospective observational study.
    Wang Y; Li Z; Chen W; Yan G; Wang G; Lu G; Chen C
    J Clin Pharm Ther; 2021 Jun; 46(3):754-761. PubMed ID: 33476064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiologically-based pharmacokinetic/pharmacodynamic modeling of meropenem in critically ill patients.
    Yang Y; Wang Y; Zeng W; Zhou J; Xu M; Lan Y; Liu L; Shen J; Zhang C; He Q
    Sci Rep; 2024 Aug; 14(1):19269. PubMed ID: 39164261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics and simulations of imipenem in critically ill patients undergoing continuous renal replacement therapy.
    Li S; Xie F
    Int J Antimicrob Agents; 2019 Jan; 53(1):98-105. PubMed ID: 30626495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetics and Dosing Optimization of Gentamicin in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.
    He S; Cheng Z; Xie F
    Drug Des Devel Ther; 2022; 16():13-22. PubMed ID: 35023902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics and probability of target attainment in patients with sepsis under renal replacement therapy receiving continuous infusion of meropenem: Sustained low-efficiency dialysis and continuous veno-venous haemodialysis.
    Westermann I; Gastine S; Müller C; Rudolph W; Peters F; Bloos F; Pletz M; Hagel S
    Br J Clin Pharmacol; 2021 Nov; 87(11):4293-4303. PubMed ID: 33818823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.